CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Dermabase.it
Farmaexplorer.it

Patients undergoing CABG: Omega-3 fatty acids do not alter P-wave parameters in electrocardiogram or expression of atrial connexins


Researchers at University of Manchester ( Manchester, UK = previously reported Omega-3 polyunsaturated fatty acids ( n-3PUFAs ) supplementation does not reduce atrial fibrillation following coronary artery bypass graft ( CABG ) surgery.

The aim of a study was to evaluate the impact of n-3 PUFAs on electrocardiogram ( ECG ) atrial arrhythmic markers and compare with expression of gap-junction proteins, connexins.

Subset of clinical trial subjects with right atrial sampling during CABG surgery included.

Twelve-lead ECG performed at recruitment and at surgery [ after supplementation with n-3 PUFA ( approximately 1.8 g/day ) or matched placebo ] for approximately 14 days.

Electrocardiograms analysed for maximum P-wave duration ( P-max ) and difference between P-max and minimum P-wave duration, P-wave dispersion ( PWD ).

Right atrial specimens analysed for expression of Connexins 40 and 43 using real-time quantitative polymerase chain reaction ( qPCR ) and western blot.

Serum levels of n-3 PUFA at baseline, at surgery, and atrial tissue levels at surgery collated from file.

Postoperative atrial fibrillation was quantified by analysing data from stored continuous electrograms.

A total of 61 patients ( n-3 PUFA, n=34, placebo, n=27 ) had ECG analysis and atrial fibrillation burden, of which 52 patients ( 26 in each group ) had qPCR and 16 ( 8 in each group ) had western blot analyses for connexins 40 and 43.

No difference between the two groups in ECG parameters or expression of connexin 40 or 43.

P-wave dispersion in the preoperative ECG independently predicted occurrence of atrial fibrillation following CABG surgery.

In conclusion, Omega-3 polyunsaturated fatty acids supplementation does not alter pro-arrhythmic P-wave parameters in ECG or connexin expression in human atrium with no effect on the incidence of atrial fibrillation following CABG surgery. ( Xagena )

Saravanan P et al, Europace 2016; Epub ahead of print

XagenaMedicine_2016



Indietro